New publication: Chiaie et al. report the results of two multicenter studies evaluating the effects of S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of 571 patients with major depression (1). The first study evaluated an oral formulation, and the second administered an intramuscular preparation. Subjects included in these investigations were diagnosed with major depressive episode with a unipolar course and no psychotic symptoms as per DSM-IV criteria. All patients had baseline Hamilton Depression Rating Scale (HAM-D) scores >18 and severity scores >4 on the Clinical Global Impression (CGI) rating scale. Only oral lorazepam (1-2.5mg daily) was allowed during the study periods for sleep induction.

Content available for subscribers only.